What is it about?
Clostridium difficile is an important nosocomial pathogen and the leading cause of antibiotics-associated diarrhea and pseudomembranous colitis. Toxin A and B are the two major virulence factors of C. difficile. The emergence and spread of antimicrobial resistance in C. difficile necessitates the development of urgent antitoxin strategies.
Featured Image
Why is it important?
This study identified the cholesterol-regulating SREBP-2 pathway as a suitable pharmacological target for the inhibition of C. difficile toxin A and B.
Perspectives
Our findings might help to develop novel treatment options against C. difficile infections.
PD Dr. Panagiotis Papatheodorou
University of Ulm Medical Center
Read the Original
This page is a summary of: Cytotoxicity of Clostridium difficile toxins A and B requires an active and functional SREBP-2 pathway, The FASEB Journal, April 2019, Federation of American Societies For Experimental Biology (FASEB),
DOI: 10.1096/fj.201801440r.
You can read the full text:
Contributors
The following have contributed to this page
